This report details recommendations for the GSK MenACWY-CRM/MenB-4C pentavalent meningococcal vaccine, Penmenvy, for individuals aged 10 years and older in the United States. Meningococcal disease, caused by Neisseria meningitidis serogroups A, B, C, W, and Y, is a serious bacterial infection. The Advisory Committee on Immunization Practices (ACIP) recommends this new vaccine as an alternative when both quadrivalent (MenACWY) and serogroup B (MenB) vaccines are indicated concurrently, particularly for healthy persons aged 16-23 years with shared clinical decision-making for MenB, and for those aged ≥10 years at increased risk. The vaccine demonstrates comparable short-term immunogenicity for most serogroups and similar safety profiles to existing vaccines.
Key note: The pentavalent vaccine offers a streamlined option for comprehensive meningococcal protection, but serogroup B-targeting vaccines from different manufacturers are not interchangeable.